MARKET

AGEN

AGEN

Agenus
NASDAQ
3.110
-0.090
-2.81%
Opening 09:30 03/05 EST
OPEN
3.140
PREV CLOSE
3.200
HIGH
3.185
LOW
3.110
VOLUME
8.90K
TURNOVER
--
52 WEEK HIGH
7.34
52 WEEK LOW
1.380
MARKET CAP
112.40M
P/E (TTM)
-1.4868
1D
5D
1M
3M
1Y
5Y
1D
Press Release: Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update
Dow Jones · 16h ago
Agenus Inc. published an update to their financial calendar
Reuters · 16h ago
AGENUS TO PROVIDE FOURTH QUARTER AND YEAR-END 2025 FINANCIAL REPORT AND CORPORATE UPDATE
Reuters · 17h ago
Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update
Barchart · 23h ago
Weekly Report: what happened at AGEN last week (0223-0227)?
Weekly Report · 3d ago
Weekly Report: what happened at AGEN last week (0216-0220)?
Weekly Report · 02/23 10:35
Agenus Data From Phase 1b C-800-01 Study Evaluating Botensilimab Shows Survival With BOT+BAL Associated With Systemic Inflammation In Blood, Tumor Immune Activity Within Tumor Microenvironment
Benzinga · 02/19 20:17
Agenus Inc. Publishes Findings on Systemic and Tumor-Microenvironment Inflammation in Botensilimab-Treated Cold, Refractory Tumors
Reuters · 02/19 20:17
More
About AGEN
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.

Webull offers Agenus Inc stock information, including NASDAQ: AGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AGEN stock methods without spending real money on the virtual paper trading platform.